Century Therapeutics Q1 net loss $31.3M; cash $334.8M; CNTY-101 data expected by year end

Century Therapeutics, Inc.

2023-Q1 EPS reported -$0.53 revenue$1,720,000

Q1 net loss $31.3M vs $37.5M prior year; R&D expenses $24.9M, G&A $8.9M.
Cash, equivalents, investments $334.8M as of March 31, 2023; cash runway into 2026.
CNTY-101 Phase 1 ELiPSE-1 trial ongoing; initial data from Schedule A expected by year end 2023.
FY2023 GAAP operating expense guidance $135-145M; non-cash stock comp $12-17M.
Leadership: Greg Russotti interim CEO (since March), Michael Diem CFO, Hy Levitsky President of R&D.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Century Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $1.7 million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2023
Revenue: $1.7 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

of $122.1 million). · Collaboration Revenue: Collaboration revenue generated through the Company’s collaboration, option and license agreement with Bristol-Myers Squibb was $1.7 million for the three months ended March 31, 2023, compared to $1.1 million for the same period in 2022. · Research and Development (R&D) expenses : R&D expenses were $24.9 million for

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Century Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-058762

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.